Clinical efficacy and safety of drug-eluting bead transarterial chemoembolization combined with targeted therapy and immune checkpoint inhibitors in the treatment of intermediate-to-advanced hepatocellular carcinoma.
[OBJECTIVE] To investigate the clinical efficacy and safety of drug-eluting bead transarterial chemoembolization(DEB-TACE) combined with targeted therapy and immune checkpoint inhibitors(ICIs) in pati
- 표본수 (n) 50
APA
Lu H, Zhou Y, et al. (2026). Clinical efficacy and safety of drug-eluting bead transarterial chemoembolization combined with targeted therapy and immune checkpoint inhibitors in the treatment of intermediate-to-advanced hepatocellular carcinoma.. Pakistan journal of medical sciences, 42(2), 303-308. https://doi.org/10.12669/pjms.42.2.13021
MLA
Lu H, et al.. "Clinical efficacy and safety of drug-eluting bead transarterial chemoembolization combined with targeted therapy and immune checkpoint inhibitors in the treatment of intermediate-to-advanced hepatocellular carcinoma.." Pakistan journal of medical sciences, vol. 42, no. 2, 2026, pp. 303-308.
PMID
41836815
Abstract
[OBJECTIVE] To investigate the clinical efficacy and safety of drug-eluting bead transarterial chemoembolization(DEB-TACE) combined with targeted therapy and immune checkpoint inhibitors(ICIs) in patients with intermediate-to-advanced hepatocellular carcinoma(HCC).
[METHODOLOGY] The clinical data of one hundred patients with intermediate-to-advanced HCC treated at The Affiliated Hospital of Hebei University between January 2021 to January 2024 were retrospectively analyzed. Patients were divided into the control group(n = 50) and the observation group(n = 50) according to the treatment regimen. The control group received DEB-TACE plus the targeted therapy lenvatinib, whereas the observation group was administered DEB-TACE plus lenvatinib and the ICI pembrolizumab. Clinical efficacy was assessed, adverse reactions occurring during the treatment period were recorded. Progression-free survival(PFS), overall survival(OS) and the cumulative survival rate (CSR) were compared between groups.
[RESULTS] The observation group demonstrated significantly higher ORR and LCR compared with the control group (both < 0.05). After treatment, serum CEA, CA199 and AFP levels were significantly reduced in both groups (all < 0.05), with greater reductions observed in the observation group ( < 0.05). Post-treatment CD3, CD8 and CD4 T-cell levels increased significantly in both groups (all < 0.05), with higher levels in the observation group than in the control group( < 0.05). The ARR did not differ significantly between groups ( > 0.05). No significant differences were observed in PFS or PFSR between groups(both > 0.05).
[CONCLUSION] The combined use of DEB-TACE, targeted therapy and an ICI demonstrates superior clinical efficacy and a favorable safety profile, which can reduce tumor marker levels, enhance immune function and prolong OS in patients with intermediate-to-advanced HCC.
[METHODOLOGY] The clinical data of one hundred patients with intermediate-to-advanced HCC treated at The Affiliated Hospital of Hebei University between January 2021 to January 2024 were retrospectively analyzed. Patients were divided into the control group(n = 50) and the observation group(n = 50) according to the treatment regimen. The control group received DEB-TACE plus the targeted therapy lenvatinib, whereas the observation group was administered DEB-TACE plus lenvatinib and the ICI pembrolizumab. Clinical efficacy was assessed, adverse reactions occurring during the treatment period were recorded. Progression-free survival(PFS), overall survival(OS) and the cumulative survival rate (CSR) were compared between groups.
[RESULTS] The observation group demonstrated significantly higher ORR and LCR compared with the control group (both < 0.05). After treatment, serum CEA, CA199 and AFP levels were significantly reduced in both groups (all < 0.05), with greater reductions observed in the observation group ( < 0.05). Post-treatment CD3, CD8 and CD4 T-cell levels increased significantly in both groups (all < 0.05), with higher levels in the observation group than in the control group( < 0.05). The ARR did not differ significantly between groups ( > 0.05). No significant differences were observed in PFS or PFSR between groups(both > 0.05).
[CONCLUSION] The combined use of DEB-TACE, targeted therapy and an ICI demonstrates superior clinical efficacy and a favorable safety profile, which can reduce tumor marker levels, enhance immune function and prolong OS in patients with intermediate-to-advanced HCC.
같은 제1저자의 인용 많은 논문 (5)
- Multifunctional copper-light synergistic prodrug nanosystems for specific reprogramming of tumour immunogenic endoplasmic reticulum stress.
- Integrated machine learning risk model for predicting radiation pneumonitis in lung cancer patients with interstitial lung disease.
- Exploring the interplay between protein conformational changes and phosphorylation in a pancreatic cancer cell and stellate cell coculture system.
- A droplet digital LAMP-based lab-on-a-disc system for multiplex allele-specific detection of tumor-derived DNA mutations.
- Association between peripheral IFN-γ cytotoxic lymphocytes and response to PD-1/PD-L1-based therapy in hepatocellular carcinoma.